Document is current
Any future updates will be listed below
-
Authors
Zhan, Haiying
Chan, Nay Nwe Nyein
Khaimova, Revekka
Aung, Thazin N.
Gaule, Patricia
Robbins, Charles J.
Rimm, David L.
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF 23-138)
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 2 July 2025
First Online: 18 July 2025
Declarations
:
: Dr. Rimm has served as a Consultant/Advisor to Astra Zeneca, Cell Signaling Technology, Cepheid, Danaher, Halda Therapeutics, Incendia, NextCure, Nucleai, PAIGE.AI, Regeneron, and Sanofi. Astra Zeneca, Cepheid, NavigateBP, NextCure, Danaher/Leica, Regeneron and Konica/Minolta currently fund, or have previously funded, research in his lab.
: This study was approved by the IRB at Yale University. This study was retrospective in nature and all information was properly de-identified; therefore, ethics approval and consent were waived.
